Cantel Medical Corp

Cantel Medical — Investor Presentation (January 2020)

31 slides from Cantel Medical's investor presentation, Jan 9, 2020

  1. Slide 1: Investor Presentation January 2020

    Investor Presentation January 2020

  2. Slide 2: Cantel is focused on providing solutions for complex reprocessing workflows

    Cantel is focused on providing solutions for complex reprocessing workflows to prevent healthcare related infections Providing comprehensive education Unique portfolio of products Leading Global Brands and clinical support to dental that deliver a “complete circle in our markets: schools, dental off

  3. Slide 3: Healthcare-Associated Infections are a Major Issue with Significant Costs to the System

    Healthcare-Associated Infections are a Major Issue with Significant Costs to the System • IFU conflicts • Old equipment • Adherence • Lack of • Costs of documentation 40M patients and $150 • High staff to changing guidelines and technology turnover limiting best in • Lack of Billion annual spend on

  4. Slide 4: Cantel by the Numbers

    Cantel by the Numbers Organic ~$1.2B ~20% Financial snapshot: GrowthTargets: Net Adjusted Medical: 8-10% Sales1 EBITDAS Rate1 Dental: 5-7% Life Sciences: Flat Unique portfolio and 75-80% Approx. 1/3 ~5% Recurring Avg. Annual M&A Net operational foundation Revenue OUS1 Revenue1 Sales Contribution2 Hi

  5. Slide 5: Path to Value Creation

    Path to Value Creation Positioning the Medical segment as the premier infection prevention solutions provider in GI and expand into strategic adjacencies Drive continued growth in Dental with comprehensive infection prevention and compliance solutions that include consumables, instruments, and instr

  6. Slide 6: MEDICAL: Endoscopy focused business in a ~$4.5B global TAM

    MEDICAL: Endoscopy focused business in a ~$4.5B global TAM growing 4-5% Endoscopy Market Opportunity Cantel’s Strategic Position Over 100M endoscopy procedures in our direct markets GI Endoscopy reprocessing leader in North America and Europe growing at low-single digits1 with large installed base a

  7. Slide 7: Our Complete Circle of Protection: Proven Solutions at each Step in the Reprocessing Cycle

    Our Complete Circle of Protection: Proven Solutions at each Step in the Reprocessing Cycle SOLUTIONS WORKFLOW Bedside Transport At the sink Procedure Transport Drying Cabinet Reprocessing Cantel Product Offerings Equipment Chemistry Consumables Service Information Technology 7

  8. Slide 8: DENTAL: Diverse dental instrument and consumables business in a ~$2.0B global TAM

    DENTAL: Diverse dental instrument and consumables business in a ~$2.0B global TAM growing 2% Dental Market Opportunity Cantel’s Strategic Position Approx. 200,000 dental professionals in the US in 20191 Global leading dental brands of Hu-Friedy & Crosstex with enduring customer relationships based o

  9. Slide 9: Hu-Friedy Acquisition

    Hu-Friedy Acquisition Company Overview Product Portfolio • Leading global provider of comprehensive portfolio of premium dental Infection Control Single-use products used to prevent instruments, proprietary Instrument Management System, and compliance Consumables cross-contamination in dental suites

  10. Slide 10: Our Complete Circle of Protection: Comprehensive Solutions from Patient to Patient

    Our Complete Circle of Protection: Comprehensive Solutions Drive Performance, Protection and Efficiency from Patient to Patient SOLUTIONS WORKFLOW Chairside Cleaning Storage Sterilization Cantel Dental Product Equipment Chemistry Consumables Services Categories 10

  11. Slide 11: Hemodialysis Water - Strategic Review Update

    Hemodialysis Water - Strategic Review Update Strategic Review Process Key Business Highlights Completed comprehensive strategic review of Multi year supply agreements now secured for top hemodialysis water business including a sale process two customers accounting for ~40% of revenue1 Best path to m

  12. Slide 12: Accelerating Growth Profile with Disciplined M&A Execution

    Accelerating Growth Profile with Disciplined M&A Execution Healthy track record of disciplined approach to M&A provides the roadmap to building Cantel's suite of products, providing an end-to-end solution in infection prevention FY14-FY19 Key M&A Metrics1 M&A Strategy STRATEGIC FIT • Align with stra

  13. Slide 13: Financial Performance—Track Record of Success

    Financial Performance—Track Record of Success $1,000 10 Yr. $900 CAGR ~13% $800 $700 $600 $500 $400 $ in in millions $ $300 $200 ~15% $100 $0 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 2,3 1,2 Net Sales Adj. EBITDAS 1. Earnings before Interest, Taxes, Depreciation, Amortization, Stock co

  14. Slide 14: Capital Allocation Priorities

    Capital Allocation Priorities 1 2 3 Invest in Organic Growth Debt Paydown M&A Strong cash flow generation Enhanced R&D and product Pursue continued acquisitions supports commitment to significantly innovation investment in the infection prevention space de-lever to mid-2x by end of FY21 Ongoing stra

  15. Slide 15: FY20 Guidance including Hu-Friedy

    FY20 Guidance including Hu-Friedy Sales Growth* FY20 Earnings per Share* FY20 Sales Growth – Reported ~25.0% to 28.0% GAAP EPS $1.85 to $1.90 Sales Growth – FX ~(1.0%) GAAP EPS V% ~40% to 44% Sales Growth – Acquisitions ~20.0% to ~22.0% Non-GAAP EPS* $2.78 to $2.83 Sales Growth – Organic ~6.0% to 7.

  16. Slide 16: Key Takeaways

    Key Takeaways Leading Market Positions with established Global Brands Circle of Infection Prevention driving comprehensive workflow solutions Disciplined investment in new technologies to drive future growth Responsible growth company leveraging operating improvements to enhance margins Accelerate g

  17. Slide 17: Appendix

    Appendix

  18. Slide 18: APPENDIX A – Select Products

    APPENDIX A – Select Products

  19. Slide 19: Selected Medical Product Portfolio

    Selected Medical Product Portfolio 01 02 03 04 05 06 07 08 1. Advantage Plus® Pass-Thru AER 5. DEFENDOTM Single Use Valves 2. No touch cassette and Hookup for Advantage System 6. Procedure Kits 3. ENDODRYTM Storage and Drying System 7. Rinse and Irrigation Tubing 4. Cleanascope® Transport System 8.

  20. Slide 20: Selected Dental Product Portfolio

    Selected Dental Product Portfolio 01 02 03 04 05 06 07 08 09 10 1. IMS® Cassettes 6. Ultrasonic Inserts 2. IMS® Cassette Wrap 7. IMS® Cassette Wrap Tape 3. Sure-Check™ Pouches 8. ConFirm™ 10 In-office Biological Monitoring System 4. VistaPure™ Water Purification System 9. Safe-Flo™ Saliva Ejectors a

  21. Slide 21: Selected Dental Product Portfolio

    Selected Dental Product Portfolio 11 12 13 14 15 16 17 18 19 11. Hand Essentials™ Skin Repair Cream and Hand Soap 16. DentaPure™ Cartridges 12. Team Vista™ Dental Waterline Cleaner 17. ClearView™ Nasal Masks 13. SteamPlus™ Type 5 Integrators 18. Digital Ultra™ Flushmount Flowmeter 14. Secure Fit™ Ma

  22. Slide 22: APPENDIX B – GAAP to Non-GAAP Reconciliations

    APPENDIX B – GAAP to Non-GAAP Reconciliations

  23. Slide 23: GAAP to Non-GAAP EPS Disclosure

    GAAP to Non-GAAP EPS Disclosure Non-GAAP financial measures contained herein supplement information previously reported in filings on Form 10-Q and Form 10-K as well as in presentations by Company management to investors, analysts and others. The information below will not be deemed “filed” for purp

  24. Slide 24: GAAP to Non-GAAP EPS Disclosure (continued)

    GAAP to Non-GAAP EPS Disclosure (continued) (b) Non-GAAP Gross Profit Rate We define non-GAAP gross profit rate, adjusted to exclude acquisition-related and restructuring-related items as management deems these items to be irregular or non-operating in nature. For the three months ended July 31, 201

  25. Slide 25: GAAP to Non-GAAP EPS Disclosure (continued)

    GAAP to Non-GAAP EPS Disclosure (continued) Acquisition-related Items Acquisition-related items consist of (i) fair value adjustments to contingent consideration and other contingent liabilities resulting from acquisitions, (ii) due diligence, integration, legal fees and other transaction costs asso

  26. Slide 26: GAAP to Non-GAAP EPS Disclosure (continued)

    GAAP to Non-GAAP EPS Disclosure (continued) Other Adjustments (continued) During fiscal 2019, we recorded an adjustment to a minor litigation matter in our consolidated financial statements. Since these costs are irregular and mask our underlying operating performance, we made an adjustment to our n

  27. Slide 27: Historical P&L Reveals Success of Growth Programs

    Historical P&L Reveals Success of Growth Programs Fiscal Year Ending 7/31/2019 ($ in millions, except per share data) CAGR: FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 ’12 -’19 Net Sales $386.5 $425.0 $488.7 $565.0 $665.0 $770.2 $871.9 $918.2 13% Gross Profit $164.2 $183.5 $213.3 $253.5 $309.2 $367.2 $4

  28. Slide 28: Strong Balance Sheet & Cash Flow Generation

    Strong Balance Sheet & Cash Flow Generation Fiscal Year 2019 Ending 7/31/2019 ($ and shares in millions) FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 Total Assets $277.9 $280.7 $321.4 $434.8 $487.7 $536.1 $584.0 $694.5 $786.4 $963.7 $1,070.4 Current Ratio 2.3:1 2.3:1 2.6:1 2.4:1 2.5:1 2.5:

  29. Slide 29: GAAP to Non-GAAP EPS Reconciliation

    GAAP to Non-GAAP EPS Reconciliation Fiscal Year 2019 Ending 7/31/2019 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 GAAP Diluted EPS1 $0.77 $0.95 $1.04 $1.15 $1.44 $1.71 $2.18 $1.32 + Intangible amortization $0.14 $0.16 $0.16 $0.21 $0.22 $0.30 $0.32 $0.39 + Acquisition related items ($0.02) ($0.02) $0.02

  30. Slide 30: Income to Adjusted EBITDAS Reconciliation

    Income to Adjusted EBITDAS Reconciliation Fiscal Year 2019 Ending 7/31/2019 ($ in millions) FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 Net Income $15.6 $19.9 $20.4 $31.3 $39.2 $43.3 $48.0 $60.0 $71.4 $91.0 $55.0 + Income taxes 9.4 11.6 10.0 16.5 21.1 25.3 28.2 34.0 34.9 26.5 20.3 + Net I

  31. Slide 31: Gross Debt to Net Debt Reconciliation

    Gross Debt to Net Debt Reconciliation Fiscal Year 2019 Ending 7/31/2019 ($ in millions) FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 Gross Debt $43.3 $21.0 $122.0 $90.0 $95.0 $80.5 $78.5 $116.0 $126.0 $200.0 $233.0 - Cash (23.4) (22.6) (18.4) (30.2) (34.1) (31.8) (31.7) (28.4) (36.6) (94.1

Cantel Medical — Investor Presentation (January 2020) on 6ix